\BOOKMARK [0][-]{chapter*.2}{Abstract}{}% 1
\BOOKMARK [0][-]{chapter*.3}{Acknowledgements}{}% 2
\BOOKMARK [0][-]{chapter*.4}{Declarations}{}% 3
\BOOKMARK [0][-]{chapter*.5}{Submitted Abstracts}{}% 4
\BOOKMARK [0][-]{chapter*.6}{Contents}{}% 5
\BOOKMARK [0][-]{chapter*.8}{List of Figures}{}% 6
\BOOKMARK [0][-]{chapter*.9}{List of Tables}{}% 7
\BOOKMARK [0][-]{chapter*.10}{Abbreviations}{}% 8
\BOOKMARK [0][-]{chapter.1}{Cross-tissue comparison of chromatin accessibility, gene expression signature and cytokine production in PsA}{}% 9
\BOOKMARK [1][-]{section.1.1}{Introduction}{chapter.1}% 10
\BOOKMARK [2][-]{subsection.1.1.1}{The relevance of cell type and tissue specificity in the study of PsA}{section.1.1}% 11
\BOOKMARK [2][-]{subsection.1.1.2}{Bulk transcriptomic studies in PsA and their limitations}{section.1.1}% 12
\BOOKMARK [2][-]{subsection.1.1.3}{Transcriptomics and proteomics at the single cell resolution}{section.1.1}% 13
\BOOKMARK [2][-]{subsection.1.1.4}{Multi-omics approach in the study of complex diseases}{section.1.1}% 14
\BOOKMARK [2][-]{subsection.1.1.5}{Integration of fine-mapping GWAS SNPs and functional data in PsA}{section.1.1}% 15
\BOOKMARK [1][-]{section.1.2}{Aims}{chapter.1}% 16
\BOOKMARK [1][-]{section.1.3}{Results}{chapter.1}% 17
\BOOKMARK [2][-]{subsection.1.3.1}{PsA patients cohort description and datasets}{section.1.3}% 18
\BOOKMARK [2][-]{subsection.1.3.2}{Immune cellular composition of blood and synovial fluid in the PsA cohort}{section.1.3}% 19
\BOOKMARK [2][-]{subsection.1.3.3}{Differential chromatin accessibility analysis in immune cells reveals differences between synovial fluid and peripheral blood}{section.1.3}% 20
\BOOKMARK [2][-]{subsection.1.3.4}{Pathway enrichment analysis highlights tissue functional differences in chromatin accessibility}{section.1.3}% 21
\BOOKMARK [2][-]{subsection.1.3.5}{Differential gene expression analysis in paired circulating and synovial immune cells}{section.1.3}% 22
\BOOKMARK [2][-]{subsection.1.3.6}{Characterisation of CD14+ monocyte heterogeneity in PsA using scRNA-seq}{section.1.3}% 23
\BOOKMARK [2][-]{subsection.1.3.7}{Integration of mass cytometry differences in protein expression with chromatin accessibility and gene expression data in PsA CD14+ monocytes.}{section.1.3}% 24
\BOOKMARK [2][-]{subsection.1.3.8}{Prioritisation and interpretation of PsA GWAS SNPs}{section.1.3}% 25
\BOOKMARK [1][-]{section.1.4}{Discussion}{chapter.1}% 26
\BOOKMARK [2][-]{subsection.1.4.1}{Characterising chromatin accessibility in PsA samples}{section.1.4}% 27
\BOOKMARK [2][-]{subsection.1.4.2}{Bulk gene expression profiling and integration with chromatin accessibility data}{section.1.4}% 28
\BOOKMARK [2][-]{subsection.1.4.3}{The relevance of monocytes and investigation of other cell types}{section.1.4}% 29
\BOOKMARK [2][-]{subsection.1.4.4}{Integration of mass cytometry, chromatin accessibility and gene expression data in CD14+ monocytes}{section.1.4}% 30
\BOOKMARK [2][-]{subsection.1.4.5}{The use of PsA functional data to inform fine-mapping GWAS loci}{section.1.4}% 31
\BOOKMARK [2][-]{subsection.1.4.6}{Limitations of the study}{section.1.4}% 32
\BOOKMARK [2][-]{subsection.1.4.7}{Conclusions}{section.1.4}% 33
\BOOKMARK [0][-]{chapter*.57}{Bibliography}{}% 34
